Patent · US Active

Human PD-L1 antibodies and methods of use therefor

US11525002B2 · kind B2 · utility

2Cited by

1References

20Claims

0Family size

Assignee

The Board of Regents of the University of Texas System · US

Inventors

Michael A. Curran · Culver City, US
Carlo Toniatti · Houston, US
Ashvin R. JAISWAL · Houston, US
Dongxing Zha · Etna, US
Kui Shin Voo · Pearland, US
Bianka Prinz · Lebanon, US
Nadthakarn Boland · 安丰镇, CN

Key dates

Filing date	Oct 10, 2018
Grant date	Dec 13, 2022
Priority date	—
Expiry date	Oct 10, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.